Cronos Group (NASDAQ:CRON) Shares Gap Up – Here’s What Happened

Posted by Stanley Muller on May 13th, 2026

Cronos Group Inc. (NASDAQ:CRON – Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $2.54, but opened at $2.78. Cronos Group shares last traded at $2.6950, with a volume of 1,531,848 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Cronos Group in a research note on Tuesday, January 27th. They set a “buy” rating on the stock. Wall Street Zen upgraded shares of Cronos Group from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. TD Securities restated a “buy” rating on shares of Cronos Group in a research note on Tuesday. Sanford C. Bernstein restated a “market perform” rating and set a $2.30 price objective on shares of Cronos Group in a research note on Wednesday, January 14th. Finally, Weiss Ratings cut shares of Cronos Group from a “hold (c)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.30.

View Our Latest Research Report on CRON

Cronos Group Stock Up 0.7%

The business’s 50 day moving average is $2.59 and its two-hundred day moving average is $2.61. The firm has a market capitalization of $1.04 billion, a P/E ratio of 277.28 and a beta of 0.87.

Cronos Group (NASDAQ:CRON – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. Cronos Group had a negative net margin of 1.14% and a negative return on equity of 1.41%. The business had revenue of $58.97 million for the quarter, compared to analysts’ expectations of $42.20 million. As a group, equities analysts anticipate that Cronos Group Inc. will post 0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cronos Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Octavia Wealth Advisors LLC bought a new stake in Cronos Group in the fourth quarter worth about $28,000. Brooklyn Investment Group raised its position in Cronos Group by 5,733.0% in the third quarter. Brooklyn Investment Group now owns 10,966 shares of the company’s stock worth $30,000 after acquiring an additional 10,778 shares in the last quarter. Swiss Life Asset Management Ltd bought a new stake in Cronos Group in the third quarter worth about $31,000. Valeo Financial Advisors LLC bought a new stake in Cronos Group in the fourth quarter worth about $30,000. Finally, Scientech Research LLC bought a new stake in Cronos Group in the third quarter worth about $32,000. 8.71% of the stock is currently owned by institutional investors.

About Cronos Group

(Get Free Report)

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.